Compare ACTG & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACTG | NBP |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 379.3M |
| IPO Year | 1995 | N/A |
| Metric | ACTG | NBP |
|---|---|---|
| Price | $5.02 | $2.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | 323.9K | ★ 955.1K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $2.10 |
| 52 Week High | $5.22 | $5.19 |
| Indicator | ACTG | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 38.96 |
| Support Level | $4.77 | $2.10 |
| Resistance Level | $5.21 | $3.80 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 63.46 | 49.25 |
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.